How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,503 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Vildagliptin - Benefit assessment according to § 35a Social Code Book V

Research question A3: combination of vildagliptin plus sulfonylurea 19 2.5.1 Information retrieval and study pool 19 2.5.2 Results on added benefit 19 2.5.3 Extent and probability of added benefit 19 2.6 Research question A4: Combination of vildagliptin plus insulin (with or without metformin) 21 2.6.1 Information retrieval and study pool 21 2.6.2 Results on added benefit 29 2.6.3 Extent and probability of added benefit 29 2.7 Research question A5: combination of vildagliptin plus sulfonylurea plus (...) by the company – RCT, direct comparison: combination of vildagliptin plus metformin vs. sulfonylurea (glimepiride) plus metformin 14 Table 9: Characteristics of the intervention of the studies included by the company – RCT, direct comparison: combination of vildagliptin plus metformin vs. sulfonylurea (glimepiride) plus metformin 15 Table 10: Overview of the reasons for exclusion of the studies – direct comparison: vildagliptin plus metformin vs. sulfonylurea (glimepiride) plus metformin 16 Table 11

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

182. Saxagliptin - Benefit assessment according to § 35a Social Code Book V

, Nathan 1999 and Turner 1998), an inappropriate patient population was studied, i.e. no patients with inadequate glycaemic control under a maximum dose of sulfonylurea: ? Patients under a suboptimal dose of a sulfonylurea were generally eligible for participating in the studies CV181040 and Birkeland 1994. After randomization, the glibenclamide dose was up-titrated in both studies. These studies therefore answer the question whether it is better to initiate dual therapy or increase the dose (...) for inadequate glycaemic control D1680L00006 RCT, double- blind a , parallel, multicentre ? Screening phase: 2 weeks ? Treatment: 24 weeks Prior treatment with a combination of metformin (XR or IR) (= 1500 mg) and sulfonylurea (= 50% of the maximum recommended dosage), both in maximum tolerated dose for at least 8 weeks before the first study visit HbA1c = 7% and = 10% on first visit Calle-Pascuale 1995 Non-RCT, open-label, parallel 4 months Prior treatment with sulfonylurea for at least 1 year

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

183. Sitagliptin - Benefit assessment according to § 35a Social Code Book V

Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research questions 11 2.3 Research question A: monotherapy with sitagliptin 13 2.3.1 Information retrieval (research question A) 13 2.3.2 Research question A1: sitagliptin versus sulfonylurea (glibenclamide, glimepiride) 15 2.3.2.1 Results on added benefit (research question A1) 16 2.3.2.2 Extent and probability of added benefit (research question A1) 17 2.3.3 Research question A2: sitagliptin versus glipizide 18 2.3.3.1 Study (...) Research question B1: sitagliptin plus metformin vs. sulfonylurea (glibenclamide, glimepiride) plus metformin 40 2.4.2.1 Studies included 40 2.4.2.2 Study characteristics (research question B1) 41 2.4.2.3 Results on added benefit (research question B1) 50 2.4.2.4 Extent and probability of added benefit (research question B1) 59 2.4.2.4.1 Assessment of added benefit at outcome level 59 2.4.2.4.2 Overall conclusion on added benefit 61 2.4.2.5 List of included studies 62 Extract of dossier assessment A13

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

184. Lixisenatide - Benefit assessment according to § 35a Social Code Book V

be increased during the first 18 weeks (according to the doctor's assessment in 1 to 2 mg steps; maximum dose: 6 mg/day) ? Metformin = 1500 mg/day ? Sitagliptin 100 mg/day (fixed dosage) ? Metformin = 1500 mg/day RCT: randomized controlled trial; vs.: versus Table 10: Characteristics of the study populations – RCT, indirect comparison 2: lixisenatide + metformin vs. sulfonylureas (glibenclamide or glimepiride) + metformin Study Group N HbA1c [%] mean (SD) Age [years] mean (SD) Sex [f/m] % BMI [kg/m 2 (...) of the benefit assessment 1 2.2 Research question 5 2.3 Research question 1: combination of lixisenatide plus metformin 8 2.3.1 Information retrieval and study pool (research question 1) 8 2.3.2 Results on added benefit (research question 1) 15 2.3.3 Extent and probability of added benefit (research question 1) 15 2.4 Research question 2: combination of lixisenatide plus sulfonylurea 15 2.4.1 Information retrieval and study pool (research question 2) 15 2.4.2 Results on added benefit (research question 2) 16

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

185. Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V

indication “saxagliptin plus metformin”, the G-BA specified the following appropriate comparator therapy (ACT): ? Metformin in combination with a sulfonylurea (glibenclamide or glimepiride) The company also cited metformin in combination with a sulfonylurea as ACT for this therapeutic indication, but without limitation to the drugs glibenclamide and glimepiride specified by the G-BA. It pointed out that the added benefit was to be derived on the basis of an approval study where the sulfonylurea glipizide (...) the combination therapy of metformin plus other DPP-4 inhibitors as an alternative comparator therapy, namely for patients who cannot be treated with sulfonylurea or for whom sulfonylurea is unsuitable, but insulin therapy is not yet indicated. According to the Extract of dossier assessment A12-16 Version 1.0 Saxagliptin/metformin – Benefit assessment acc. to § 35a Social Code Book V 13.02.2013 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - information given by the company, this limitation

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

186. Dapagliflozin - Benefit assessment according to § 35a Social Code Book V

Research question 7 2.3 Information retrieval and study pool 10 2.3.1 Studies included 11 2.3.1.1 Dapagliflozin monotherapy (coding A) 11 2.3.1.2 Combination therapy of dapagliflozin and metformin (coding B) 12 2.3.1.3 Combination therapy of dapagliflozin and sulfonylureas (coding C) 13 2.3.1.4 Combination therapy of dapagliflozin and insulin (coding D) 13 2.3.1.5 Summary 14 2.4 Results on added benefit 15 2.5 Extent and probability of added benefit 15 2.5.1 Dapagliflozin monotherapy (coding A) 15 (...) 2.5.2 Combination therapy of dapagliflozin and metformin (coding B) 15 2.5.3 Combination therapy of dapagliflozin and sulfonylureas (coding C) 15 2.5.4 Combination therapy of dapagliflozin and insulin (coding D) 16 2.6 List of included studies 16 References for English extract 16 Extract of dossier assessment A12-18 Version 1.0 Dapagliflozin – Benefit assessment acc. to § 35a Social Code Book V 12.03.2013 Institute for Quality and Efficiency in Health Care (IQWiG) - iv - List of tables 3 Table 2

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

187. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada

are they intended to set criteria for research protocols. These guidelines are intended to inform general patterns of care. These guidelines are also intended to enhance diabetes prevention efforts in Canada and to reduce the burdenofdiabetescomplicationsinpeoplelivingwiththisdisease. As per the Canadian Medical Association Handbook on Clinical Practice Guidelines (Davis D, et al. Ottawa, ON: Canadian Medical Association; 2007), guidelines should not be used as a legal resourceinmalpracticecasesas (...) ofadultswithdiabetes.TwochaptersdType1DiabetesinChildren and Adolescents and Type 2 Diabetes in Children and Adoles- centsdare included to highlight aspects of care that must be tailored to the pediatric population. Suggested Citation To cite as a whole: Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical PracticeGuidelinesforthePreventionandManagementofDiabetes in Canada. Can J Diabetes 2013;37(suppl 1):S1-S212. To cite a speci?c chapter: Last, First M. "Chapter Title." Journal

2013 CPG Infobase

188. Lyxumia (lixisenatide)

Lyxumia (lixisenatide) Report on the Deliberation Results May 31, 2013 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Lyxumia Subcutaneous Injection 300 µg [Non-proprietary name] Lixisenatide (JAN*) [Name of applicant] Sanofi K.K. [Date of application] June 11, 2012 [Results of deliberation] In the meeting held on May 24, 2013, the First Committee on New Drugs concluded that the product may be approved (...) and elderly patients (limited numbers of these patients were included in clinical studies), the safety and efficacy of the product in combination with a sulfonylurea and high-dose metformin, and the long-term safety and efficacy of the product in combination with basal insulin, etc. need to be further investigated via post-marketing surveillance. As a result of its regulatory review, the Pharmaceuticals and Medical Devices Agency has concluded that the product may be approved for the following indication

2013 Pharmaceuticals and Medical Devices Agency, Japan

189. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada : Diabetes in the elderly

, side effects and adverse drug interactions . Drugs that can be considered first for deprescribing in these individuals include statins and sulfonylureas, because of lack of benefit in people with limited life expectancy and concerns about hypoglycemia, respectively. Diabetes in Long-Term Care The prevalence of diabetes is high in institutions and individuals frequently have established microvascular and CV complications, as well as substantial comorbidity . Canadian data shows over 25% of residents (...) because the risk of hypoglycemia increases substantially with age [Grade D, Level 4 ]. DPP-4 inhibitors should be used over sulfonylureas as second-line therapy to metformin because of a lower risk of hypoglycemia [Grade B, Level 2 ] In general, initial doses of sulphonylureas in the older person should be half of those used for younger people, and doses should be increased more slowly [Grade D, Consensus] Gliclazide and gliclazide MR [Grade B, Level 2 ] and glimepiride [Grade C, Level 3 ] should

2013 CPG Infobase

190. Second- and Third-line Therapies for Type 2 Diabetes

nutrition, and adequate exercise), medications, such as metformin and sulfonylureas, play an important role in achieving glycemic control in patients with diabetes mellitus: Metformin is a popular first-line oral antidiabetes drug that is used to help control glycemic levels in patients with diabetes when lifestyle modifications alone are insufficient. Because diabetes is a progressive disease, metformin monotherapy may eventually fail to adequately control glycemic levels. At this point, most patients (...) need one or more oral antidiabetes drug, or insulin, added as a second-line therapy to their treatment regimen. If, after time, second-line therapy fails, most patients will need one or more additional drugs added as a third-line therapy to achieve target glycemic levels. In Canada, seven classes of antidiabetes drugs are available that may be used as second- and third-line therapy: sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinediones, incretin agents, weight loss agents

2015 CADTH - Optimal Use

191. Empagliflozin (Jardiance) - type 2 diabetes mellitus

measures is a prerequisite to drug treatment for glycaemic control. Drug strategy: According to the HAS guidelines, if the glycaemic target is not met despite the implementation of lifestyle and dietary measures, monotherapy should be started with metformin as the first-line treatment or, if there are contraindications, with sulfonylureas. If both these drugs are contraindicated, the alternatives are: - repaglinide in patients who eat at irregular intervals, since it is administered with every meal (...) (short half-life); - alpha-glucosidase inhibitors if episodes of hypoglycaemia give cause for concern. If there are symptoms or very poorly controlled diabetes with recurrent blood glucose levels above 3 g/l or with an HbA1c greater than 10%, dual therapy or insulin therapy may be initiated from the start. Combinations recommended as dual therapy: If the glycaemic target is not achieved with monotherapy, dual therapy is recommended, combining metformin and sulfonylureas as first-line treatment

2015 Haute Autorite de sante

192. Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2010 Clinical Trials

193. The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea

Interaction Between CKD-501 and Sulfonylurea (CKD-501 DDI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01133431 Recruitment Status : Completed First Posted : May 28, 2010 Last Update Posted : December 10, 2010 Sponsor: Chong Kun Dang Pharmaceutical Information provided by: Chong Kun Dang Pharmaceutical (...) The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Pharmacokinetic

2010 Clinical Trials

194. Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea

or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 20 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas > half maximal dose, and metformin > 1500 mg/d) for > 10 weeks (...) Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2010 Clinical Trials

195. Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.

number of saved studies (100). Please remove one or more studies before adding more. Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01244646 Recruitment Status : Terminated First (...) . For general information, Layout table for eligibility information Ages Eligible for Study: 35 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Probability Sample Study Population General practitioners, group practices in primary care, pharmacists Criteria Inclusion Criteria: Diabetes Mellitus Type 2 for > 6 months on treatment with only metformin for >4 weeks HbA1c value >7.0 and therefore a sulfonylurea derivative is added Able to complete

2010 Clinical Trials

196. A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

studies (100). Please remove one or more studies before adding more. A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01242215 Recruitment Status : Completed First Posted : November 16, 2010 (...) Astellas Pharma Inc More Information Go to Additional Information: Layout table for additonal information Responsible Party: Astellas Pharma Inc ClinicalTrials.gov Identifier: Other Study ID Numbers: 1941-CL-0109 First Posted: November 16, 2010 Last Update Posted: January 20, 2016 Last Verified: January 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Astellas Pharma Inc: ASP1941 Diabetes mellitus sulfonylurea Additional relevant MeSH terms

2010 Clinical Trials

197. Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2010 Clinical Trials

198. A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2010 Clinical Trials

199. Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation Full Text available with Trip Pro

Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation Sulfonylurea receptor-containing ATP-sensitive potassium (K(ATP)) channels have been implicated in cardioprotection, but the cell type and constitution of channels responsible for this protection have not been clear. Mice deleted for the first nucleotide binding region of sulfonylurea receptor 2 (SUR2) are referred to as SUR2 null since they lack full-length SUR2 and glibenclamide-responsive K (...) (ATP) channels in cardiac, skeletal, and smooth muscle. As previously reported, SUR2 null mice develop electrocardiographic changes of ST segment elevation that were shown to correlate with coronary artery vasospasm. Here we restored expression of the cardiomyocyte SUR2-K(ATP) channel in SUR2 null mice by generating transgenic mice with ventricular cardiomyocyte-restricted expression of SUR2A. Introduction of the cardiomyocyte SUR2A transgene into the SUR2 null background restored functional

2010 American Journal of Physiology - Heart and Circulatory Physiology

200. The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01404676 Recruitment Status : Completed First Posted : July 28, 2011 Last Update Posted : September 18, 2018 Sponsor: Samsung Medical Center Collaborator: Novartis Information provided by (Responsible Party): Samsung Medical Center Study Details Study Description Go to Brief Summary: The effect of vildagliptin based treatment versus sulfonylurea based treatment on glycemic variability, oxidative (...) The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>